Boehringer Ingelheim Partners With SBP Group on Cancer
The collaboration covers six biologic pre-clinical programs targeting next-generation cancer treatments based on antibody-drug conjugate and T-cell engager technologies.
Updated on Nov. 4, 2026 in Cancer
Boehringer Ingelheim has entered a multi-program option and license agreement with SBP Group, which will receive US$358 million in upfront and near-term payments. SBP Group is also eligible for US$7 billion in potential milestone payments.
Why it matters
The deal advances early-stage biologic cancer candidates while giving Boehringer Ingelheim options on exclusive rights after agreed clinical milestones are reached. Cancer causes approximately 20.6 million new cases and close to 10 million deaths annually worldwide.
The agreement carries US$358 million in upfront and near-term payments against up to US$7 billion in potential milestones across six pre-clinical programs. Whether any program clears the clinical milestones needed to trigger option exercise has not been disclosed.
The players
Boehringer Ingelheim
A privately held German pharmaceutical company headquartered in Ingelheim, Germany, with approximately 54,300 employees, which recently opened a China R&D Center in Shanghai.
SBP Group
A Chinese biopharmaceutical group with over 20,000 employees that develops antibody-drug conjugate and T-cell engager cancer therapies through subsidiaries LaNova Medicines and Beijing Tide Pharmaceutical.
The details
SBP Group will undertake early development of the six programs, five centered on its wholly owned subsidiary LaNova Medicines in Shanghai and one from subsidiary Beijing Tide Pharmaceutical. Boehringer Ingelheim may later exercise options for exclusive development, manufacturing and commercialization rights, outside mainland China, Hong Kong and Macau for four programs and worldwide for two.
Timeline
4 November 2026: Boehringer Ingelheim and SBP Group announced the agreement.
Big Picture
The agreement follows a wider pattern of global drugmakers licensing early-stage oncology biologics from Chinese developers, with territorial carve-outs for mainland China, Hong Kong and Macau. It positions Boehringer Ingelheim's new Shanghai R&D Center within that cross-border pipeline.
The programs are pre-clinical, so no new treatment is available to patients yet. Any eventual therapies would still need clinical trials and regulatory approval before reaching cancer patients.
The takeaway
Early-stage cancer research increasingly moves across borders through licensing, so patients may eventually benefit from therapies developed in several countries. Readers should expect a long path from pre-clinical programs to approved treatments.
Further reading
Explore more in Cancer coverage on biologic treatment development.
